Aeras and its research partners.

We are extraordinarily grateful because of their foresight and steadfast support of these potentially life saving efforts. Related StoriesNew research may offer strategies for developing toxoplasma-inactivated vaccineSinovac Dalian receives authorization to start human medical trials of varicella vaccine candidateResearch provides leads for new strategies to develop HIV vaccineTB is one of the world’s deadliest infectious diseases, killing 2 million men nearly, women and children each year. Despite global efforts to prevent and deal with TB, the epidemic is now more complex and tough to diagnose and deal with due in large part to the emergence of drug-resistant types of TB and the emergence of the HIV epidemic. TB is in charge of the majority of Helps deaths in Africa.Grobler, Ph.D., Lise Werner, M.Sc., Angela Kashuba, Pharm.D., Leila E. Mansoor, Ph.D., Natasha Samsunder, B.Tech., Adrian Mindel, M.D., and Tanuja N. Gengiah, Ph.D. For the CAPRISA 004 Trial Group: Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection Globally, herpes simplex virus type 2 infection is among the most common sexually transmitted infections and may be the leading reason behind genital ulcers.